Business professionals should read the story of Theranos as a cautionary tale that carries at least two big lessons.
Wikipedia
Theranos is an American privately held consumer health-technology company based in Palo Alto, California.[1] It is under criminal investigation by federal prosecutors and the Securities and Exchange Commission.[2]
Theranos developed a blood-testing device named Edison. The company said the device uses a few drops of blood obtained via a finger-stick, rather than vials of blood obtained via traditional venipuncture,[3] utilizing microfluidics technology.[4] By the summer of 2014, its founders had raised over $400 million from investors, valuing the company at $9 billion.[5][6]
In October 2015, controversy surrounding the company's blood testing process arose after a report in The Wall Street Journal raised concerns about the accuracy of its Edison device. An independent U.S. government review by the Centers for Medicare and Medicaid Services (CMS) reported inaccurate testing results and multiple deficiencies in sample handling during a recent inspection.
On July 7, 2016, Theranos announced that it had received notice from the Centers for Medicare & Medicaid Services (CMS) regarding the revocation of its CLIA certificate. Sanctions include a prohibition of the owners and operators from owning or operating a lab for two years and a civil monetary penalty.[9][10]
On October 5, 2016, Theranos announced that it would close its laboratory operations, shutter its wellness centers and lay off around 40 percent of its work force, while henceforth focusing on an initiative to create miniature medical testing machines.[11]
沒有留言:
張貼留言